Three New Drugs for Hereditary Angioedema
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary
angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Three New Drugs for Hereditary Angioedema
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1345
Article Code: 1345b
Date: August 23, 2010
Volume: 52
Pages: 66-67
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1345
Article Code: 1345b
Date: August 23, 2010
Volume: 52
Pages: 66-67
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)